X-101398419-A-G
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000169.3(GLA):c.950T>C(p.Ile317Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000912 in 1,097,023 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome AF: 9.12e-7 AC: 1AN: 1097023Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 362397
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:1
This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 317 of the GLA protein (p.Ile317Thr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Fabry disease (PMID: 11914245, 12175777, 17040996, 18023222, 23305247). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 844415). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLA protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. -
Cardiovascular phenotype Pathogenic:1
The p.I317T pathogenic mutation (also known as c.950T>C), located in coding exon 6 of the GLA gene, results from a T to C substitution at nucleotide position 950. The isoleucine at codon 317 is replaced by threonine, an amino acid with similar properties. This alteration has been reported in numerous individuals with Fabry disease, including individuals with deficient alpha-galactosidase enzyme activity and symptoms, such as renal insufficiency and cardiac disease (Sachdev B et al. Circulation, 2002 Mar;105:1407-11; Shabbeer J et al. Mol Genet Metab, 2002 May;76:23-30; Merta M et al. Nephrol Dial Transplant, 2007 Jan;22:179-86; Auray-Blais C et al. Mol Genet Metab, 2008 Mar;93:331-40; Chen X et al. ESC Heart Fail, 2021 Dec;8:5436-5444; Effraimidis G et al. PLoS One, 2022 Nov;17:e0277767; Nakamura K et al. Mol Genet Metab Rep, 2023 Sep;36:100983). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at